The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
21 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $12,173,124 in first-year total cost, median $569,944.
Most frequent study sections
- Special Emphasis Panel[ZRG1 BST-F (55)]8
- Special Emphasis Panel[ZRG1 OBT-Y (56)]6
- Drug Discovery and Molecular Pharmacology Study Section[DMP]2
- Special Emphasis Panel[ZRG1 BST-W (55)]2
- Drug Discovery and Molecular Pharmacology B Study Section[DMPB]1
Most frequent institutions
- SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE2
- BAYLOR COLLEGE OF MEDICINE1
- BECKMAN RESEARCH INSTITUTE/CITY OF HOPE1
- BRIGHAM AND WOMEN'S HOSPITAL1
- BROAD INSTITUTE, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2023 | Targeting the mutant promoter of Telomerase Reverse Transcriptase (TERT)1R01CA275078-01A1 | JACKSON, MICHAELTHEODORESCU, DAN | CEDARS-SINAI MEDICAL CENTER, CA | $772,180 | DMP |
| 2023 | Identification of small molecule inhibitors of the DDI2 protease1R01CA279255-01 | KLEIGER, GARY L.RADHAKRISHNAN, SENTHIL KUMARSERGIENKO, EDUARD A. | VIRGINIA COMMONWEALTH UNIVERSITY, VA | $730,979 | DMP |
| 2023 | Development of Kv3.1 potentiators for correcting fast-spiking-interneuron hypofunction in schizophrenia and autism spectrum disorder1R01MH131721-01A1 | DENTON, JEROD S. | VANDERBILT UNIVERSITY MEDICAL CENTER, TN | $695,775 | DMPB |
| 2023 | Discovery of Novel Inhibitors Targeting trans-Golgi Network Acidification in Pancreatic Cancer1R01CA276193-01 | COMMISSO, COSIMOHEYNEN-GENEL, SUSANNE | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, CA | $647,398 | ZRG1 |
| 2023 | Identification of small molecule inhibitors to exonuclease 1 for breast cancer treatment1U01CA276195-01A1 | HORNE, DAVID A.SHEN, BINGHUI | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $575,395 | DMPC |
| 2023 | Screening for inhibitors of NSD3 as a treatment for lung cancer1R01CA276074-01 | GREMBECKA, JOLANTA | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $529,475 | ZRG1 |
| 2022 | Small molecule enhancers of tumor immunity targeting the LPA5 GPCR1R01CA266207-01A1 | AUGELLI-SZAFRAN, CORINNE ELIZABETHLEE, SUE CHINTIGYI, GABOR JTORRES, RAUL MARTIN | UNIVERSITY OF TENNESSEE HEALTH SCI CTR, TN | $861,845 | ZRG1 |
| 2022 | Targeting Postsynaptic Small G-protein Regulators1R01MH130838-01 | LUAN, CHI-HAOPENZES, PETER | NORTHWESTERN UNIVERSITY AT CHICAGO, IL | $733,531 | ZRG1 |
| 2022 | Targeting platinum(IV) prodrug to GBM tumors using a brevican-binding peptide1R01CA272573-01 | CHO, CHOI-FONG | BRIGHAM AND WOMEN'S HOSPITAL, MA | $701,557 | ZRG1 |
| 2022 | Development of p300/CBP histone acetyltransferase inhibitors for oncogene-driven cancers1R01CA266642-01 | HAHN, WILLIAM C. | BROAD INSTITUTE, INC., MA | $682,670 | ZRG1 |
| 2022 | Identification and characterization of chemical probes for interrogation of the NEK family of kinases in cancer1R01CA273095-01 | BUROW, MATTHEW E.DREWRY, DAVID HAROLDNEWMAN, ROBERT HOWARD | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $636,146 | ZRG1 |
| 2022 | Discovery of Glutaryl-CoA Dehydrogenase inhibitors for melanoma and pancreatic cancer1R01CA266828-01 | SERGIENKO, EDUARD A. | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, CA | $569,944 | ZRG1 |
| 2022 | Discovery of small molecule inhibitors for protein N-terminal acetyltransferase D1R01CA258887-01A1 | HUANG, RONG | PURDUE UNIVERSITY, IN | $559,725 | ZRG1 |
| 2022 | Development of a generalizable chemo-proteomics screening platform for small molecule degraders applied to HDACs1R01CA262188-01A1 | FISCHER, ERIC SEBASTIAN | DANA-FARBER CANCER INST, MA | $487,238 | ZRG1 |
| 2022 | High Throughput Screen for Inhibitors of the YEATS2 Histone Acylation Reader1R01CA268440-01 | SHI, XIAOBING | VAN ANDEL RESEARCH INSTITUTE, MI | $445,463 | ZRG1 |
| 2022 | Small molecules to target the RNA methyltransferase complex METTL3/METTL141R01CA258589-01A1 | NAM, YUNSUN | UT SOUTHWESTERN MEDICAL CENTER, TX | $440,678 | ZRG1 |
| 2022 | Novel Small-Molecule Probes Targeting Oncogenic Fusion MLL in Pediatric Leukemia1R01CA266057-01 | SONG, YONGCHENG | BAYLOR COLLEGE OF MEDICINE, TX | $437,571 | ZRG1 |
| 2022 | High Throughput Screening for SCAP Inhibitors as Pancreas Cancer Therapeutics1R01CA272789-01 | ESPENSHADE, PETER J. | JOHNS HOPKINS UNIVERSITY, MD | $405,491 | ZRG1 |
| 2021 | A Fragment-Based Strategy for K-RAS Covalent Inhibitors1R01CA264471-01 | MEROUEH, SAMY | INDIANA UNIVERSITY INDIANAPOLIS, IN | $469,217 | ZRG1 |
| 2021 | High-Throughput Screen for the Oncoprotein MYC1R01CA262290-01 | JANDA, KIM | SCRIPPS RESEARCH INSTITUTE, THE, CA | $432,947 | ZRG1 |
| 2021 | Discovery of small molecule mutant SMAD4-PPI inducers1R37CA255459-01A1 | MO, XIULEI | EMORY UNIVERSITY, GA | $357,899 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.